Search

15 For '19: Key Clinical Data to Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in...

RAKUTEN ASPYRIAN ENROLLING PHASE 3 TRIAL OF ASP-1929 FOR HEAD AND NECK CANCER

SAN DIEGO, Dec. 17, 2018 /PRNewswire/ - Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based...

 
 
 

SOPHIRIS BIO PROVIDES UPDATES ON PHASE 2B LOCALIZED PROSTATE CANCER TRIAL

Reiterates plans to move to Phase 3 with single administration of topsalysin SAN DIEGO and VANCOUVER, British Columbia, Dec. 17, 2018...

15 For '19: Key Clinical Data To Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

It can take decades and billions of dollars to develop a drug, and its fate-and often that of its developer-rests in the outcome of...

 
 
 

EVOFEM BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 3 STUDY EVALUATING AMPHORA FOR HORMONE-FREE BIRTH CONTROL

Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed - Q2 2019...

PRECLINICAL OPPORTUNITY - PART TIME

Great opportunity for individual with scientific software experience/knowledge. Position is 100% telecommuting based. 40 year old software...

 
 
 
Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More

BIO ROUNDUP: ELI LILLY TRIES TAU, GENERIC INSULIN, NASH CASH & MORE

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used...

Eli Lilly Partners with AC Immune on Tau Blockers for Alzheimer's

ELI LILLY PARTNERS WITH AC IMMUNE ON TAU BLOCKERS FOR ALZHEIMER'S

There's at least one major pharmaceutical company that isn't giving up yet on finding an Alzheimer's disease drug. Eli Lilly is pairing...

 
 
 
To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health

TO COVER DEBTS, SYNERGY INKS $200M BANKRUPTCY SALE TO BAUSCH HEALTH

Synergy Pharmaceuticals has spent years looking for a buyer. The developer of a struggling drug for two types of chronic constipation...

 
 
 
Membrion Gets $2.2M for Materials to Help Store Energy, Purify Water

MEMBRION GETS $2.2M FOR MATERIALS TO HELP STORE ENERGY, PURIFY WATER

Inspiration can come from unlikely places-like the bottom of a bag of beef jerky, for instance. Membrion , a Seattle-based cleantech...

Half a Million Tests and Many Mosquitoes Later, New Buzz about a Malaria Prevention Drug

HALF A MILLION TESTS AND MANY MOSQUITOES LATER, NEW BUZZ ABOUT A MALARIA PREVENTION DRUG

Researchers spent two years testing chemical compounds for their ability to inhibit the malaria parasite at an earlier stage in its...

 
 
 
Brii Bio's Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline

BRII BIO'S ALLIANCE WITH VBI VACCINES ADDS HEPATITIS B DRUG TO PIPELINE

Brii Biosciences launched earlier this year with $260 million and a mission to find new medicines in infectious disease and other therapeutic...

Impel Raises $67.5M to Advance Intranasal Drugs for CNS Disorders

IMPEL RAISES $67.5M TO ADVANCE INTRANASAL DRUGS FOR CNS DISORDERS

Impel NeuroPharma , which is developing technology to deliver certain therapeutics more effectively to the brain, says it has raised...

 
 
 
Infant ibuprofen sold at Walmart, CVS, Family Dollar recalled over dosage concerns

INFANT IBUPROFEN SOLD AT WALMART, CVS, FAMILY DOLLAR RECALLED OVER DOSAGE CONCERNS

MONMOUTH JUNCTION, N.J. - A New Jersey-based pharmaceutical company is recalling three lots of liquid infant ibuprofen, sold at Walmart,...

OncoMed's Saga Ends in Reverse Merger with UK-Based Mereo BioPharma

ONCOMED'S SAGA ENDS IN REVERSE MERGER WITH UK-BASED MEREO BIOPHARMA

OncoMed Pharmaceuticals attracted hundreds of millions of dollars from investors and pharmaceutical partners with compounds it developed...

 
 
 

AMGEN ANNOUNCES FIRST-IN-HUMAN DATA EVALUATING INVESTIGATIONAL NOVEL BITE® IMMUNOTHERAPIES AMG 420 AND AMG 330 AT ASH 2018

Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid LeukemiaFDA Grants...

 
 
 

METABOLIC ENGINEERING OF THE THERMOPHILIC FILAMENTOUS FUNGUS MYCELIOPHTHORA THERMOPHILA TO PRODUCE FUMARIC ACID

Fumaric acid is widely used in food and pharmaceutical industries and is recognized as a versatile industrial chemical feedstock. Increasing...

CAR T-CELL THERAPIES SHOW DURABLE RESPONSES, NEW RESEARCH ALSO EXPLORES COMBINATION THERAPIES TO EXTEND AND ENHANCE TREATMENT RESPONSES

SAN DIEGO, Dec. 3, 2018 /PRNewswire/ - Chimeric antigen receptor T-cell therapies have quickly shifted the treatment paradigm for many...